Evidence map›Paper›PMID 39927629›Full record

ReviewJournal of the Pediatric Infectious Diseases Society2025

Mechanisms and Manifestations of Group B Streptococcus Meningitis in Newborns.

Natalie G Alexander, William D Cutts, Thomas A Hooven, Brandon J Kim

Abstract readReview
In one paragraph

Review in Journal of the Pediatric Infectious Diseases Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. A cross-strain CRISPRi sgRNA library forMicrobiology resource announcements · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Hyperglycemia enhances group BFrontiers in immunology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Natalie G AlexanderDepartment of Biological Sciences, University of Alabama, Tuscaloosa, Alabama, USA.
William D CuttsDepartment of Biological Sciences, University of Alabama, Tuscaloosa, Alabama, USA.ORCID 0000-0002-7881-2127
Thomas A HoovenDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Brandon J KimDepartment of Biological Sciences, University of Alabama, Tuscaloosa, Alabama, USA.

Funding

A Rationally Targeted Approach to Preventing GBS InfectionK08AI132555 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOOVEN, THOMAS A · 2018 to 2021
$769k
Genome-wide assessment of Group B Streptococcus fitness and virulenceR21AI147511 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOOVEN, THOMAS A, RATNER, ADAM JONATHAN · 2020 to 2021
$489k
Impairment of the cerebral vasculature during bacterial meningitisR15NS131921 · NINDS · UNIVERSITY OF ALABAMA IN TUSCALOOSA · PI CORRELL, ROBERT NATHAN · 2023 to 2023
$447k
A Group B Streptococcus ordered CRISPR interference library to investigate host-pathogen interactionsR03AI185593 · NIAID · UNIVERSITY OF TEXAS DALLAS · PI KIM, BRANDON JONATHAN · 2024 to 2025
$153k
National Institute of Allergy and Infectious Diseases R03AI185593NIAID NIH HHS K08 AI132555NIAID NIH HHS R03 AI185593NIAID NIH HHS R21 AI147511NINDS NIH HHS R15 NS131921NINDS NIH HHS R15NS131921
6 · The paper itself

Abstract

Group B Streptococcus (GBS; Streptococcus agalactiae) is a gram-positive colonizer of the healthy intestinal and genitourinary microbiota. During and shortly after birth, neonates and infants can be opportunistically infected leading to sepsis, pneumonia, or meningitis among other illnesses. GBS is the leading cause of neonatal meningitis globally, and while prophylactic treatments have been successful for reducing early-onset disease, no decrease in the incidence of late-onset disease has occurred and no vaccine is currently available. In this review, we describe GBS both from a clinical and molecular standpoint. We first describe the history of GBS perinatal disease and its clinical presentation and treatment, as well as patient outcomes. We then present recently discovered GBS interactions at the blood-brain barrier that contribute to disease and inflammatory responses, and efforts to develop a broadly effective GBS vaccine.

Indexed as

Meningitis, BacterialStreptococcal InfectionsStreptococcus agalactiaeBlood-Brain BarrierHumansInfant, NewbornStreptococcal VaccinesStreptococcal Vaccinesblood–brain barrierclinical outcomeshost–pathogen interactionsmeningitisStreptococcus

Identifiers

PMID39927629
PMCPMC11808573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.